The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial

Abstract

This study was designed to evaluate the effects of colchicine in the improvement of clinical outcomes of hospitalized COVID-19 patients. This prospective, randomized, double-blind, placebo-controlled clinical trial was conducted on adult patients (>18 years) with severe COVID-19. The included patients were randomly (1:1) assigned to the colchicine (2 mg loading dose followed by 0.5 mg twice daily for 7 days) or placebo group. Both groups received remdesivir and interferon beta-1b. The primary outcome of the study was to receive clinical response as ordinal scale of 1 or 2. Secondary outcomes were hospital complications and 28-day mortality. Between February and May 2021, 110 patients were included and 106 of them were analyzed. Baseline clinical characteristics and demographics were not significantly different. According to the ordinal scale, 30 patients in the control group (58.8%) responded to treatment within 7 days, while 35 patients (63.6%) in the colchicine group showed the same response (p = 0.61, odds ratio (OR) = 1.23, 95% CI [0.560–2.68]). On the 14th day, 87.3% of the colchicine group (n = 48) and 82.4% of the control group (n = 42) responded (p = 0.48, OR = 1.47, 95% CI [0.50.3–4.29]. In addition, 28-day mortality, intensive care unit admission, and hospital duration were not different between the groups (p = 0.99, 0.59, 0.06). Diarrhea and nausea were the major side effects dominant in the colchicine group. Colchicine showed no beneficial effects on clinical improvement and hospital complications in patients with COVID-19. Moreover, in case of prescription, the safety concerns of colchicine, specially gastrointestinal side effects, should be taken into account.

Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials

“…A total of 23 RCTs (28 249 participants) were eligible for inclusion in our meta-analysis 15–37. The details of the screening process are presented in figure 1.…”

Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial

“…This preliminary evidence provided the rationale for several studies testing colchicine in patients with COVID-19 (Table 1). Although there is accumulating evidence on the use of colchicine in hospitalized patients with moderate-to-severe COVID-19, 20–26 this treatment strategy has been tested only in a single study in the out-of-hospital setting 27 . In the COLCORONA trial, colchicine was associated with significantly lower rates of the composite outcome of death or hospital admission compared with placebo among out-of-hospital patients with PCR-confirmed COVID-19 27 …”

CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome

“…One more approach of the treatment is using colchicine, an indirect IL-6 inhibitor, which is also applied in the treatment of coronary heart disease ( Bonifácio et al, 2023 ). Colchicine suppresses the recruitment of neutrophils, inhibits cytoskeleton metabolism, and opposes SARS-CoV-2 functionality in human cells ( Kasiri et al, 2023 ). Rodriguez et al suggested IL-8 antagonists to be prospective agents to treat severe coronavirus infection ( Rodriguez et al, 2021 ).…”